M. Bahadoor

Can pathologic complete response (pCR) be used as a surrogate marker of survival after neoadjuvant therapy for breast cancer?

Frédérique Penault-Llorca, F. Penault-Llorca, N. Radosevic-Robin, 2015, Critical reviews in oncology/hematology.

Response to Induction Neoadjuvant Hormonal Therapy Using Upfront 21-Gene Breast Recurrence Score Assay—Results From the SAFIA Phase III Trial

S. Kullab, H. Abdel-Razeq, A. Bensalem, 2021, JCO global oncology.

Multicentric neoadjuvant phase II study of panitumumab combined with an anthracycline/taxane-based chemotherapy in operable triple-negative breast cancer: identification of biologically defined signatures predicting treatment impact.

F. Penault-Llorca, N. Radosevic-Robin, T. Petit, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Multicentric neoadjuvant pilot Phase II study of cetuximab combined with docetaxel in operable triple negative breast cancer

F. Penault-Llorca, N. Radosevic-Robin, M. Mouret-Reynier, 2016, International journal of cancer.

Breast-cancer detection using blood-based infrared molecular fingerprints

F. Krausz, Abdallah Mohammed Azzeer, S. Kullab, 2021, BMC Cancer.

Neoadjuvant endocrine therapy with or without palbociclib in low-risk patients: a phase III randomized double-blind SAFIA trial

Ghosn, H. Abdel-Razeq, A. Bensalem, 2023, Journal of Cancer Research and Clinical Oncology.

Prospective study of the energy balance disruption during adjuvant chemotherapy in post-menopausal early-stage breast cancer patient

Pascale Fung, M. Mouret-Reynier, B. Morio, 2020 .

Satisfaction of Cancer Patients Treated with Oral Anticancer Medications regarding Dispensing by Community Pharmacists: A Cross-Sectional Study

J. Bay, C. Pétorin, D. Balayssac, 2023, European Journal of Cancer Care.